Drug details:
Molecular formula: C₅₆H₄₂O₁₂

Standard name: (1R,8R,9S,16R)-8,16-bis(4-hydroxyphenyl)-9-[(1R,8R,9S,16R)-4,6,12-trihydroxy-8,16-bis(4-hydroxyphenyl)-15-oxatetracyclo[8.6.1.02,7.014,17]heptadeca-2(7),3,5,10(17),11,13-hexaen-9-yl]-15-oxatetracyclo[8.6.1.02,7.014,17]heptadeca-2(7),3,5,10(17),11,13-hexaene-4,6,12-triol

Synonyms:

Hopeaphenol (1R)-1alpha,7alpha-Bis(4-hydroxyphenyl)-6beta-[(1R)-1alpha,7alpha-bis(4-hydroxyphenyl)-4,8,10-trihydroxy-1,6,7,11balpha-tetrahydrobenzo[6,7]cyclohepta[1,2,3-cd]benzofuran-6beta-yl]-1,6,7,11balpha-tetrahydrobenzo[6,7]cyclohepta[1,2,3-cd]benzofuran-4,8,10-triol

Curated SMILES: C1=CC(=CC=C1C2C(C3=C4C(C(OC4=CC(=C3)O)C5=CC=C(C=C5)O)C6=C2C(=CC(=C6)O)O)C7C(C8=C(C=C(C=C8O)O)C9C(OC1=CC(=CC7=C91)O)C1=CC=C(C=C1)O)C1=CC=C(C=C1)O)O

Evidence for compound's anti-virulence activity:

Pseudomonas
Related VF: TTSS (Type III secretion system)
Target: Not determined
Drug effect: Inhibits T3SS.
Max phase: Preclinical (in vivo)
Publication:
Zetterström CE, et al., 2013. The resveratrol tetramer (-)-hopeaphenol inhibits type III secretion in the gram-negative pathogens Yersinia pseudotuberculosis and Pseudomonas aeruginosa. PLoS One 8(12):e81969.

Yersinia
Related VF: TTSS (Type III secretion system)
Target: Targets possibly are located on the bacterial cell surface
Drug effect: An irreversible inhibitor of Yop secretion.
Max phase: Preclinical (in vivo)
Publication:
Zetterström CE, et al., 2013. The resveratrol tetramer (-)-hopeaphenol inhibits type III secretion in the gram-negative pathogens Yersinia pseudotuberculosis and Pseudomonas aeruginosa. PLoS One 8(12):e81969.